Cover Image
市場調查報告書

氣喘及慢性阻塞性肺疾病治療藥市場預測:對主要業者的市場機會

Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs

出版商 Visiongain Ltd 商品編碼 214196
出版日期 內容資訊 英文 314 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
氣喘及慢性阻塞性肺疾病治療藥市場預測:對主要業者的市場機會 Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs
出版日期: 2016年10月25日 內容資訊: 英文 314 Pages
簡介

預估全球氣喘及COPD(慢性阻塞性肺疾病)治療藥市場收益將於2019年達到358億7,000萬美元規模,至2025年將展現高度收益成長。預估全球高齡人口的增加與呼吸系統疾病發病率升高預估將提升銷售額。

本報告調查全球氣喘及COPD(慢性阻塞性肺疾病)治療藥市場,提供以地區/主要國家、藥劑分類的市場現況及各種趨勢、市場規模及市場佔比推估預測、主要業者、主要藥劑、開發趨勢等。

第1章 報告概要

第2章 氣喘及COPD治療藥:簡介

  • 醫藥品產業概要
  • 呼吸疾病概要
  • 什麼是氣喘?
    • 盛行率趨勢
    • 病理生理學
    • 氣喘症狀
    • 原因與發病
    • 氣喘治療
    • 治療準則
    • 藥物治療
    • 投藥方法
  • 什麼是COPD(慢性阻塞性肺疾病)?
    • 盛行率趨勢
    • 病理生理學
    • 病徵與症狀
    • 治療
    • 藥物治療
    • 投藥方法
  • 氣喘及COPD治療的主要藥物類別
    • 支氣管擴張劑
      • Beta2-Agonists
      • 抗膽鹼性藥物
    • 消炎藥
      • 皮質類固醇(ICS)
      • 白三烯受體拮抗劑
      • 呼吸疾病治療的單株抗體
    • 複方藥物
  • 臨床試驗階段
  • 研究範圍
  • 匯率

第3章 氣喘及COPD治療藥:全球市場預測

  • 全球呼吸系統相關治療藥市場:按治療領域分類
  • 全球氣喘及COPD治療藥
    • 主要治療藥
    • 主要業者
  • 全球呼吸系統相關治療藥市場:按治療領域銷售額分類
    • 氣喘
    • COPD
  • 全球呼吸系統相關治療藥市場:按藥物類別銷售額預測
  • 複方藥物領導市場
  • 市場佔比變化預測
  • 氣喘及COPD治療藥:各種趨勢

第4章 主要國家市場預測

  • 區域明細
  • 區域預測
  • 各國明細
  • 國家市場預測
  • 美國
  • 日本
  • EU 5國
  • BRIC各國
  • 墨西哥

第5章 支氣管擴張劑的單一藥物治療市場

  • 支氣管擴張劑的單一藥物治療:簡介
  • 支氣管擴張劑的單一藥物治療市場
  • 支氣管擴張劑的單一藥物治療:市場預測
  • 藥物分類的市場佔比變化預測
  • SABA(Short-Acting Beta2-Agonist)市場預測
    • 目前主要SABA
    • SABA:市場預測
    • 主要SABA市場佔比預測
    • Ventolin (salbutamol, GSK)
    • ProAir (salbutamol, Teva)
    • Proventil (salbutamol, Merck)
    • Xopenex (levosalbutamol, Dainippon Sumitomo)
  • LABA(Long-Acting Beta2-Agonist)市場預測
    • 目前主要LABA
    • LABA:市場預測
    • 主要LABA市場佔比預測
    • Foradil (formoterol, Merck/Novartis)
    • Brovana (arfomoterol, GSK)
    • Arcapta/Onbrez (indacaterol, Novartis)
    • Serevent (salmeterol,Dainippon Sumitomo)
  • 抗膽鹼性藥物市場預測
    • 目前主要抗膽鹼性藥物
    • 抗膽鹼性藥物:市場預測
    • 主要抗膽鹼性藥物市場佔比預測
    • Spiriva (tiotropium, Boehringer Ingelheim)
    • Atrovent (ipratropium, Boehringer Ingelheim)
    • Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)

第6章 消炎藥市場預測

  • 簡介:消炎藥
  • 消炎藥市場
  • 主要消炎藥現況
  • 消炎藥:市場預測
  • 藥物分類的市場佔比變化預測
  • 皮質類固醇市場預測
    • 主要皮質類固醇現況
    • 皮質類固醇:市場預測
    • 主要皮質類固醇市場佔比預測
    • Flixotide/Flovent (fluticasone propionate, GSK)
    • Pulmicort (budesonide, AstraZeneca)
    • QVAR (beclometasone, Teva)
    • Asmanex (mometasone, Merck)
  • 抗白三烯藥物市場預測
    • 主要抗白三烯藥物現況
    • 抗白三烯藥物:市場預測
    • Singulair (montelukast, Merck)
  • 單株抗體市場預測
    • 單株抗體:市場預測
    • Xolair (omalizumab, Novartis/Roche)
    • Cinquil (reslizumab, Teva)
    • Mepolizumab (Bosatria, GSK)
    • Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
    • Lebrikizumab (RG3637, Roche)
    • Dupilumab (REGN668, Regeneron/Sanofi)

第7章 複方藥物市場預測

  • 簡介:複方藥
  • 複合藥:市場預測
  • 市場佔比變化預測
    • Advair/Seretide (fluticasone/salmeterol, GSK)
    • Symbicort (budesonide/formoterol, AstraZeneca)
    • Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
    • Dulera (formoterol/mometasone, Merck)
  • 近期發售的複方藥

第8章 主要企業

  • 競爭加劇
  • GSK
  • Boehringer Ingelheim
  • AstraZeneca
  • Merck & Co. (Merck)
  • Novartis
  • Roche
  • Teva

第9章 氣喘及COPD治療藥的開發分析預測

  • 活潑的氣喘及COPD開發
  • 支氣管擴張藥開發
    • 支氣管擴張藥:第3階段開發
      • PX1439□PX1442 (Prosonix)
      • PT001 (glycopyrronium, AstraZeneca)
      • Spiriva Respimat (tiotropium, Boehringer Ingelheim)
      • GW642444 (vilanterol, GSK)
      • KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
      • Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
      • QVAR BAI (beclometasone, Teva)
      • Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
  • 消炎藥開發
    • 消炎藥:第3階段開發
      • PSX1001□PSX1050 (fluticasone propionate pMDI, Prosonix)
      • Masitinib (tyrosine kinase inhibitor, AB Science)
      • Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
      • VR506 (fluticasone propionate DPI, Vectura)
      • Favolir (budesonide, Vectura)
  • 複方藥開發
    • 複方藥:第3階段開發
      • PSX2005 (fluticasone/salmeterol, Prosonix)
      • LAS40464 (aclidinium/formoterol, AstraZeneca)
      • PT003 (glycopyrronium/formoterol, AstraZeneca)
      • Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
      • Easyhaler 複方藥 (Orion)
      • VR632 (ICS/LABA, Vectura/Sandoz)
  • 其他氣喘及COPD治療藥開發

第10章 定性分析

  • SWOT分析
  • 波特五力分析;氣喘及COPD治療藥市場

第11章 研究採訪

  • Clive Page教授(Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London)
  • 進行氣喘及COPD開發藥開發的企業

第12章 結論

  • 氣喘及COPD治療藥:市場日趨成熟
  • 全球氣喘及COPD治療藥市場現況
  • 全球氣喘及COPD治療藥市場預測
  • 氣喘及COPD治療藥市場未來

第13章 詞彙表

  • 附錄A
  • 附錄B

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0149

Visiongain's comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016.

Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report.

It's vital that you keep your knowledge up to date. You need this report.

Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers.

The asthma & COPD Market 2016-2026 report responds to your need for definitive market data:

  • Where are the asthma & COPD market opportunities ?
    • 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively
  • When will the asthma & COPD market grow ?
    • Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression
  • Which asthma & COPD submarkets will flourish from 2016-2026 ?
    • Individual application forecasts and analysis demonstrate the prospects
  • Combination drugs forecast 2016-2026
  • Anti-inflammatory drugs forecast 2016-2026
    • Corticosteroids forecast 2016-2026
    • Anti-Leukotrienes forecast 2016-2026
    • Monoclonal antibodies forecast 2016-2026
    • Other anti-inflammatories forecast 2016-2026
  • Bronchodilator monotherapy forecast 2016-2026
    • Short-acting beta2-agonist (SABAs) forecast 2016-2026
    • Long-acting beta2-agonist (LABAs) forecast 2016-2026
    • Anticholinergics forecast 2016-2026
  • Where are the regional asthma & COPD market opportunities from 2016-2026 ?
    • Focused regional forecasts and analysis explore the future opportunities
    • US forecast 2016-2026,
    • China forecast 2016-2026
    • Japan forecast 2016-2026
    • India forecast 2016-2026
    • Germany forecast 2016-2026
    • UK forecast 2016-2026
    • France forecast 2016-2026
    • Mexico forecast 2016-2026
    • Brazil forecast 2016-2026
    • Russia forecast 2016-2026
  • What are the factors influencing asthma & COPD market dynamics ?
    • SWOT / Porter's Five Forces analysis explores the factors.
    • Research and development (R&D) strategy
    • Technological issues and constraints.
    • Supply and demand dynamics
    • Competition from new product types
    • Increasing specialisation by leading players
    • Advances in product quality
  • Who are the leading asthma & COPD companies ?
    • Examine competitive positioning, product portfolios, R&D activity, M&A activity, and future outlook.
    • GSK
    • Boehringer Ingelheim
    • AstraZeneca
    • Merck & Co. Inc (Merck)
    • Novartis
    • Roche
    • Teva

image1

  • Who should read this report ?
    • Anyone within the asthma & COPD value chain, including
    • CEO's
    • COO's
    • CIO's
    • Business development managers
    • Marketing managers
    • Suppliers
    • Technologists
    • Investors
    • Banks
    • Government agencies
    • Contractors

Table of Contents

1. Report Overview

  • 1.1 Global Asthma and COPD Therapies Market Overview
  • 1.2 Global Asthma and COPD Therapies Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies

  • 2.1 The Pharmaceutical Industry: A Very Brief Overview
  • 2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
    • 2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
  • 2.3 What is Asthma?
    • 2.3.1 Trends in Asthma Prevalence
    • 2.3.2 Pathophysiology of Asthma
    • 2.3.3 Symptoms of Asthma
    • 2.3.4 Causes and Triggers for Asthma
    • 2.3.5 Treatment of Asthma
    • 2.3.6 Guidelines for Asthma Treatment
    • 2.3.7 Drug Treatments for Asthma
    • 2.3.8 Drug Delivery Methods in Asthma
  • 2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
    • 2.4.1 Trends in COPD Prevalence
    • 2.4.2 Pathophysiology of COPD
    • 2.4.3 Signs and Symptoms of COPD
    • 2.4.4 Treatment of COPD
    • 2.4.5 Drug Treatments for COPD
    • 2.4.6 Guidelines for COPD Treatment
  • 2.5 Major Drug Classes in the Treatment of Asthma and COPD
    • 2.5.1 Bronchodilators
      • 2.5.1.1 Beta2-Agonists
      • 2.5.1.2 Anticholinergics
    • 2.5.2 Anti-Inflammatory Drugs
      • 2.5.2.1 Corticosteroids
      • 2.5.2.2 Leukotriene Receptor Antagonists
      • 2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
    • 2.5.3 Combination Drugs
  • 2.6 Phases of Clinical Trials
  • 2.7 Scope of this Report
  • 2.8 Currency Exchange Rates in This Report

3. Asthma and COPD Therapies: Global Market 2016-2026

  • 3.1 The Global Respiratory Drugs Market by Therapeutic Area
  • 3.2 The Global Asthma and COPD Therapies Market in 2016
    • 3.2.1 Leading Asthma and COPD Therapies
    • 3.2.2 Leading Companies in the Asthma and COPD Therapies Market
  • 3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2026
    • 3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2026
    • 3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2026
  • 3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2026
  • 3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
  • 3.6 How Will Segmental Shares Change to 2026
    • 3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2026
  • 3.7 Asthma and COPD Therapies: Trends and Developments
    • 3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
    • 3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Bronchodilator Monotherapy Market 2016-2026

  • 4.1 Introduction to Bronchodilator Monotherapy
  • 4.2 The Bronchodilator Monotherapy Market in 2015
    • 4.2.1 Leading Bronchodilators in 2015
    • 4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2026
    • 4.2.3 How Will Market Shares by Drug Class Change to 2026?
  • 4.3 The Anticholinergics Market 2016-2026
    • 4.3.1 Leading Anticholinergics in 2015
    • 4.3.2 Anticholinergics: Market Forecast 2016-2026
    • 4.3.3 Market Share of Leading Anticholinergics to 2026
    • 4.3.4 Spiriva (tiotropium. Boehringer Ingelheim)
      • 4.3.4.1 Spiriva: Sales Forecast 2016-2026
      • 4.3.4.2 Spiriva: Recent Developments
    • 4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
      • 4.3.5.1 Atrovent: Sales Forecast 2016-2026
    • 4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
      • 4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2016-2026
  • 4.4 The SABAs Market 2016-2016
    • 4.4.1 Leading SABAs in 2015
    • 4.4.2 SABAs: Market Forecast 2016-2026
    • 4.4.3 Market Share of Leading SABAs to 2026
    • 4.4.4 Ventolin (salbutamol, GSK)
      • 4.4.4.1 Ventolin: Sales Forecast 2016-2026
    • 4.4.5 ProAir (salbutamol, Teva)
      • 4.4.5.1 ProAir: Sales Forecast 2016-2026
    • 4.4.6 Proventil (salbutamol, Merck)
      • 4.4.6.1 Proventil: Sales Forecast 2016-2026
    • 4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
      • 4.4.7.1 Xopenex: Sales Forecast 2016-2026
  • 4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2026
    • 4.5.1 Leading LABAs in 2015
    • 4.5.2 LABAs: Market Forecast 2016-2026
    • 4.5.3 Market Share of Leading LABAs to 2026
    • 4.5.4 Foradil (formoterol, Merck/Novartis
      • 4.5.4.1 Foradil: Sales Forecast 2016-2026
    • 4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
      • 4.5.5.1 Brovana: Sales Forecast 2016-2026
    • 4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
      • 4.5.6.1 Arcapta/Onbrez: Sales Forecast 2016-2026
    • 4.5.7 Severent (salmeterol, GSK)
      • 4.5.7.1 Serevent: Sales Forecast 2016-2026

5. Anti-inflammatory Drugs Market 2016-2026

  • 5.1 Introduction to Anti-Inflammatory Drugs
  • 5.2 The Anti-Inflammatory Drugs Market in 2015
    • 5.2.1 Leading Anti-Inflammatory Drugs in 2015
    • 5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2026
    • 5.2.3 How Will Market Shares by Drug Class Change to 2026?
  • 5.3 The Corticosteroids Market 2016-2026
    • 5.3.1 Leading Corticosteroids in 2015
    • 5.3.2 Corticosteroids: Market Forecast 2016-2026
    • 5.3.3 Market Share of Leading Corticosteroids to 2026
    • 5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
      • 5.3.4.1 Flixotide/Flovent: Sales Forecast 2016-2026
    • 5.3.5 Pulmicort (budesonide, AstraZeneca)
      • 5.3.5.1 Pulmicort: Sales Forecast 2016-2026
    • 5.3.6 QVAR (beclometasone, Teva)
      • 5.3.6.1 QVAR: Sales Forecast 2016-2026
    • 5.3.7 Asmanex (mometasone, Merck)
      • 5.3.7.1 Asmanex: Sales Forecast 2016-2026
  • 5.4 The Anti-Leukotrienes Market 2016-2026
    • 5.4.1 Leading Anti-Leukotrienes in 2015
    • 5.4.2 Anti-Leukotrienes: Market Forecast 2016-2026
    • 5.4.3 Market Share of Leading Anti-Leukotrienes to 2026
    • 5.4.4 Singulair (montelukast, Merck)
      • 5.4.4.1 Singulair: Sales Forecast 2016-2026
  • 5.5 The Monoclonal Antibodies Market 2016-2026
    • 5.5.1 Monoclonal Antibodies: Market Forecast 2016-2026
    • 5.5.2 Market Share of Leading Monoclonal Antibodies to 2026
    • 5.5.3 Xolair (omalizumab, Novartis/Roche)
      • 5.5.3.1 Xolair: Sales Forecast 2016-2026
    • 5.5.4 Cinquil (reslizumab, Teva)
      • 5.5.4.1 Cinquil: Sales Forecast 2016-2026
    • 5.5.5 Nucala (Mepolizumab, GSK)
      • 5.5.5.1 Nucala: Sales Forecast 2016-2026
    • 5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
      • 5.5.6.1 Benralizumab: Sales Forecast 2016-2026
    • 5.5.7 Lebrikizumab (RG3637, Roche)
      • 5.5.7.1 Lebrikizumab: Sales Forecast 2016-2026
    • 5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
      • 5.5.8.1 Dupilumab: Sales Forecast 2016-2026

6. Combination Drugs Market 2016-2026

  • 6.1 Introduction to Combination Drugs
    • 6.1.1 Leading Combination Drugs in 2015
    • 6.1.2 Combination Drugs: Market Forecast 2016-2026
    • 6.1.3 How Will Market Shares by Drug Change to 2026?
    • 6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
      • 6.1.4.1 Advair/Seretide: Sales Forecast 2016-2026
    • 6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
      • 6.1.5.1 Symbicort: Sales Forecast 2016-2026
      • 6.1.5.2 Symbicort: The SMART Concept
    • 6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
      • 6.1.6.1 Combivent: Sales Forecast 2016-2026
    • 6.1.7 Dulera (formoterol/mometasone, Merck)
      • 6.1.7.1 Dulera: Sales Forecast 2016-2026
    • 6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
      • 6.1.8.1 Breo/Relvar: Sales Forecast 2016-2026
  • 6.2 Recently Launched Combination Drugs

7. Leading National Markets 2016-2026

  • 7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
  • 7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2026
    • 7.2.1 How Will Regional Market Shares Change to 2026?
    • 7.2.2 National Breakdown of the Global asthma and COPD Therapies Market
    • 7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2026
    • 7.2.4 How Will National Market Shares Change to 2026?
  • 7.3 The US Asthma and COPD Therapies Market 2016-2026
    • 7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.3.2 US Asthma and COPD Therapies Market Trends and Developments
      • 7.3.2.1 Increasing COPD Prevalence in the US
      • 7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
      • 7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
  • 7.4 Japanese Asthma and COPD Therapies Market 2016-2026
    • 7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
      • 7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
      • 7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
  • 7.5 EU5 Asthma and COPD Therapies Market 2016-2026
    • 7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
      • 7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 7.5.6.2 France: Social Security Finance Bill 2015
      • 7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
      • 7.5.6.4 Italy: Austerity Measures Limiting Growth
      • 7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
  • 7.6 BRIC Asthma and COPD Therapies Market 2016-2026
    • 7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
      • 7.6.2.1 China's Industrial Future and Asthma/COPD
      • 7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
      • 7.6.2.3 Price Controls and the Anhui Model
    • 7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
      • 7.6.4.1 Increasing Access to Medicines
    • 7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
      • 7.6.6.1 Drug Prices Control Order 2013
      • 7.6.6.2 Expansion of Healthcare Provision
    • 7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
      • 7.6.8.1 No Embargo on Foreign Drug Imports
      • 7.6.8.2 Pharma2020 and the Russian Pharmaceutical Industry
  • 7.7 Mexican Asthma and COPD Therapies Market 2016-2026
    • 7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2026
    • 7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
      • 7.7.2.1 Seguro Popular: Mexican Healthcare Reform
      • 7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
      • 7.7.2.3 Mexico's Agreement for Innovation

8. Leading Companies in the Asthma and COPD Therapies Market

  • 8.1 Asthma and COPD Therapies: Increasing Competition
  • 8.2 Leading Companies in Asthma and COPD in 2015
  • 8.3 Leading Companies: Market Forecast 2016-2026
  • 8.4 How Will Leading Companies' Market Shares Change to 2026?
  • 8.5 GSK
    • 8.5.1 GSK: Asthma and COPD Therapies
    • 8.5.2 GSK: Sales Forecast 2016-2026
    • 8.5.3 GSK: Products in Development
    • 8.5.4 GSK: Recent Developments
      • 8.5.4.1 Recently Launched Combination Drugs
      • 8.5.4.2 GSK Divests OTC Products
      • 8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
      • 8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
  • 8.6 Boehringer Ingelheim
    • 8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
    • 8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2026
    • 8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
    • 8.6.4 Boehringer Ingelheim: Recent Developments
      • 8.6.4.1 Expansion of Respimat Manufacturing Capacity
      • 8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
      • 8.6.4.3 Ben Venue Laboratories Shut Down
      • 8.6.4.4 Sale of Roxane Laboratories
      • 8.6.4.5 Spiloto Respimat and the PHYSACTO Study
  • 8.7 AstraZeneca
    • 8.7.1 AstraZeneca: Asthma and COPD Therapies
    • 8.7.2 AstraZeneca: Sales Forecast 2016-2026
    • 8.7.3 AstraZeneca: Products in Development
    • 8.7.4 AstraZeneca: Recent Developments
      • 8.7.4.1 AstraZeneca Acquires Almirall's Respiratory Portfolio
      • 8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca's Combination Drug Pipeline
      • 8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
      • 8.7.4.4 AstraZeneca Acquires Right to Actavis' Branded Respiratory Portfolio in US and Canada
      • 8.7.4.5 Takeda Respiratory Portfolio Acquisition
  • 8.8 Merck & Co. (Merck)
    • 8.8.1 Merck: Asthma and COPD Therapies
    • 8.8.2 Merck: Sales Forecast 2016-2026
    • 8.8.3 Merck: Products in Development
    • 8.8.4 Merck: Recent Developments
      • 8.8.4.1 Bayer Acquires Merck's Consumer Health Business
      • 8.8.4.2 FDA Rejects Singulair OTC Switch
      • 8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
  • 8.9 Novartis
    • 8.9.1 Novartis: Asthma and COPD Therapies
    • 8.9.2 Novartis: Sales Forecast 2016-2026
    • 8.9.3 Novartis: Products in Development
    • 8.9.4 Novartis: Recent Developments
      • 8.9.4.1 Novartis Restructures Following Strategic Review
      • 8.9.4.2 Novartis Presents Data on Ultibro and Seebri
      • 8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
  • 8.10 Roche
    • 8.10.1 Roche: Asthma and COPD Therapies
    • 8.10.2 Roche: Sales Forecast 2016-2026
    • 8.10.3 Roche: Products in Development
  • 8.11 Teva
    • 8.11.1 Teva: Asthma and COPD Therapies
    • 8.11.2 Teva: Sales Forecast 2016-2026
    • 8.11.3 Teva: Products in Development
    • 8.11.4 Teva: Recent Developments
      • 8.11.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2016-2026

  • 9.1 A Strong Asthma and COPD Pipeline
  • 9.2 The Bronchodilators Pipeline
  • 9.3 Bronchodilators: Phase 3 Pipeline
    • 9.3.1 PX1439 and PX1442 (Prosonix)
    • 9.3.2 PT001 (glycopyrronium, AstraZeneca)
    • 9.3.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
    • 9.3.4 GW642444 (vilanterol, GSK)
    • 9.3.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
    • 9.3.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
    • 9.3.7 QVAR BAI (beclometasone, Teva)
    • 9.3.8 Albuterol MDPI/Albuterol RespiClick (salbutamol, Teva)
  • 9.4 The Anti-Inflammatory Drugs Pipeline
  • 9.5 Anti-Inflammatory Drugs: Phase 3 Pipeline
    • 9.5.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
    • 9.5.2 Masitinib (tyrosine kinase inhibitor, AB Science)
    • 9.5.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
    • 9.5.4 VR506 (fluticasone propionate DPI, Vectura)
    • 9.5.5 Favolir (budesonide, Vectura)
  • 9.6 The Combination Drugs Pipeline
  • 9.7 Combination Drugs: Phase 3 Pipeline
    • 9.7.1 Seriveo (fluticasone/salmeterol, Circassia) (Formerly PSX2005 (Prosonix))
    • 9.7.2 Duaklir Genuair (LAS40464) (aclidinium/formoterol, AstraZeneca)
    • 9.7.3 Bevespi Aerosphere (PT003) (glycopyrronium/formoterol, AstraZeneca)
    • 9.7.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
    • 9.7.5 Easyhaler Combination Drugs (Orion)
    • 9.7.6 VR632 (ICS/LABA, Vectura/Sandoz)
  • 9.8 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2026

  • 10.1 SWOT Analysis of the Asthma and COPD Therapies Market
  • 10.2 Strengths
    • 10.2.1 Increasing Prevalence and Disease Burden
    • 10.2.2 High Costs of Treatment
    • 10.2.3 The Changing Perception of COPD
    • 10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
    • 10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
    • 10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
    • 10.2.7 Developments in Diagnostics
      • 10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
      • 10.2.7.2 Biological Markers in COPD
  • 10.3 Weaknesses
    • 10.3.1 Under-Diagnosis: the 'Ghost Population'
    • 10.3.2 Side-Effects of Drug Classes
    • 10.3.3 Patent Cliff for Devices
    • 10.3.4 Low Patient Adherence
    • 10.3.5 Costing Pressures in both Developed and Emerging Markets
  • 10.4 Opportunities
    • 10.4.1 Patient Phenotyping and Personalised Medicine
    • 10.4.2 A Strong R&D Pipeline
    • 10.4.3 Ultra-Long-Acting Beta2-Agonists
    • 10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
    • 10.4.5 Monoclonal Antibodies
    • 10.4.6 LAMA/LABA Combinations
    • 10.4.7 Opportunities in Telehealth
  • 10.5 Threats
    • 10.5.1 Patent Expiry and Generic Competition
    • 10.5.2 Pharmacy Benefit Managers and Cost Control
    • 10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
  • 10.6 Porter's Five Forces Analysis of the Asthma and COPD Therapies Market
    • 10.6.1 Rivalry among Competitors [Medium]
    • 10.6.2 Threat of New Entrants [Medium]
    • 10.6.3 Power of Suppliers [Medium]
    • 10.6.4 Power of Buyers [High]
    • 10.6.5 Threat of Substitutes [Low]

11. Conclusions

  • 11.1 Asthma and COPD Therapies: A Maturing Market
  • 11.2 The Global Asthma and COPD Therapies Market in 2015
  • 11.3 Current Leading Asthma and COPD Therapies Segments
    • 11.3.1 Leading Asthma and COPD Therapies
    • 11.3.2 Leading Asthma and COPD Therapies Companies
    • 11.4 Leading Regional and National Markets
  • 11.5 Global Asthma and COPD Therapies Market Forecast 2016-2026
  • 11.6 The Future of the Asthma and COPD Therapies Market
    • 11.6.1 Growth in Anti-Inflammatory and Combination Drugs
    • 11.6.2 Personalised Medicine
    • 11.6.3 Unmet Needs in Asthma and COPD
  • 11.7 Strategies for Growth in 2016-2026

12. Glossary

  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

Table of Figures

  • Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2016
  • Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016
  • Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2016
  • Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2015
  • Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2015
  • Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2015
  • Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2015
  • Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2020
  • Figure 3.10 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2026
  • Figure 3.11 World Asthma and COPD Therapies Market: Drivers and Restraints, 2016-2026
  • Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2015
  • Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2020
  • Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2026
  • Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2015
  • Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2020
  • Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2026
  • Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2015
  • Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2020
  • Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2026
  • Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2015
  • Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2020
  • Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2026
  • Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2015-2026
  • Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2015
  • Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2015
  • Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2020
  • Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2020
  • Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2025
  • Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2025
  • Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2015
  • Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2020
  • Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2026
  • Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2015
  • Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2020
  • Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2026
  • Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2020
  • Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2026
  • Figure 5.24 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.25 Teva: Cinquil Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.26 GSK: Nucala Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.27 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.28 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2015-2026
  • Figure 5.29 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2015
  • Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2020
  • Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2026
  • Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2015-2026
  • Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2015-2026
  • Figure 7.1 World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2015
  • Figure 7.2 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2015
  • Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2015-2026
  • Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2020
  • Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2026
  • Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2015
  • Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2015
  • Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2020
  • Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2026
  • Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2015-2026
  • Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2015-2026
  • Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2015-2026
  • Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2015-2026
  • Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2015
  • Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2015
  • Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2020
  • Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2020
  • Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2026
  • Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2026
  • Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2015
  • Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2015
  • Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2015-2026
  • Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2016-2026
  • Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2016-2026
  • Figure 10.3 Porter's Five Forces Analysis of the Asthma and COPD Therapies Market, 2016-2026
  • Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2015-2026

Table of Tables

  • Table 2.1 Classification of Respiratory Diseases, 2016
  • Table 2.2 Causes of Asthma, 2016
  • Table 2.3 Triggers of Asthma, 2016
  • Table 2.4 Clinical Trial Phases
  • Table 2.5 Currency Exchange Rates, 2015
  • Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2015
  • Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2015
  • Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
  • Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2015, 2020 and 2026
  • Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2015
  • Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2015
  • Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
  • Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2015
  • Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.10 Leading SABAs in 2015
  • Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 4.12 SABAs Market: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2015
  • Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2015
  • Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2015
  • Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2015-2026
  • Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2026
  • Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2015
  • Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2015, 2020 and 2026
  • Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2015-2026
  • Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2015
  • Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.19 Teva: Cinquil Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2015
  • Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2015, 2020 and 2026
  • Table 6.4 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2015-2026
  • Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2015
  • Table 7.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2015-2026
  • Table 7.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2015, 2020 and 2026
  • Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2015
  • Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
  • Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026 (continued)
  • Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2015, 2020 and 2026
  • Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
  • Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2015-2026
  • Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2015
  • Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
  • Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2020 and 2026
  • Table 8.4 GSK: Overview, 2015
  • Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
  • Table 8.7 GSK: Asthma and COPD Therapies Pipeline, 2015
  • Table 8.8 Boehringer Ingelheim: Overview, 2015
  • Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 8.11 AstraZeneca: Overview, 2015
  • Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2015-2026
  • Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline, 2016
  • Table 8.15 Merck: Overview, 2015
  • Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
  • Table 8.18 Novartis: Overview, 2015
  • Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
  • Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2015
  • Table 8.22 Roche: Overview, 2015
  • Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
  • Table 8.24 Teva: Overview, 2015
  • Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2015
  • Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2015-2026
  • Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2015
  • Table 9.1 Bronchodilators Pipeline: Selected Phase 3 Drugs, 2016
  • Table 9.2 Anti-Inflammatory Drugs Pipeline: Selected Phase 3 Drugs, 2016
  • Table 9.3 Combination Drugs Pipeline: Selected Phase 3 Drugs, 2016
  • Table 9.4 Other Asthma and COPD Drugs Pipeline, 2016

Companies Listed

  • 3M Drug Delivery Systems
  • AB Science
  • Actavis
  • Alcon
  • Alembic
  • Allen and Hanburys
  • Allergan
  • Almirall
  • Apotex
  • Ario Pharma
  • Array BioPharma
  • Aspen Pharmacare
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo Pharma
  • Bellephron
  • Ben Vue Laboratories
  • BioWa
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Breath Limited
  • Bristol-Meyer Squibbs
  • Catalent Pharma Solutions
  • Cephalon
  • Ception Therapeutics
  • Chiesi Pharmaceuticals
  • Ciba-Geigy
  • Cipla
  • Circassia Pharmaceuticals
  • CVS Caremark
  • Daewoong Pharmaceutical
  • Dainippon Sumimoto
  • Dr. Reddy's Laboratories
  • Express Scripts
  • Forest Pharmaceuticals
  • Fountain Biopharma
  • Genentech (Roche)
  • Grifols
  • GSK
  • Hikma Pharmaceuticals
  • Ikaria
  • Invion
  • Kamada
  • Kyorin Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lilly
  • Mariposa
  • MedicNova
  • Medimmune
  • Menarini
  • Merck & Co.
  • Mylan
  • Novartis
  • Nycomed
  • Omega Pharma
  • Orion Pharmaceuticals
  • Pearl Therapeutics
  • Perrigo
  • Pfizer
  • Prosonix
  • Reckitt Becnkiser
  • Regeneron
  • Roche
  • Roxane Laboratories
  • Sandoz (Novaris)
  • Sanofi
  • Schering-Plough's
  • SkyePharma
  • Sofotec
  • Stempeutics
  • Sunovion Pharmaceuticals
  • Synairgen
  • Takeda Pharmaceuticals
  • Tanox
  • Teva
  • Theravance
  • Vectura
  • Viatris
  • Watson (Actavis)

Organisations Mentioned in the Report

  • American Lung Association
  • Bank of Spain
  • Bundesministerium fur Gesundheit (German Ministry of Health)
  • Brazilian Unified Health System (SUS)
  • Department of Pharmaceuticals (India)
  • European Lung Foundation
  • European Respiratory Foundation
  • European Respiratory Society
  • Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
  • Global Initiative for Asthma (GINA)
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD)
  • Italian Medicines Agency (AIFA)
  • Italian Servicio Sanitario Nazionale (SSN)
  • Japanese Pharmaceuticals and Medical Devices Agency
  • Pan-American Health Organization (PAHO)
  • Seguro Popular (Mexico)
  • UK National Health Service (NHS)
  • US Centers For Disease Control and Prevention (CDC)
  • US Food and Drug Administration (FDA)
  • US Institutes of Health
Back to Top